(CDAX, Renewables, ABO GR)



Buy eur 3.50	(EUR 4.00)	DCF: 3.53 Ba		Warburg Risk Score: Balance Sheet Score: Market Liquidity Score:	2.3 4.0 0.5	Description: Independent power producer (IPP), operating onshore wind and PV projects in Europe		
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2025e	
		Market cap:	127.57	Freefloat	72.80 %	Beta:	0.8	
Price	EUR 1.70	No. of shares (m):	75.04	Tion Renewables	21.90 %	Price / Book:	0.8 x	
Upside	105.9 %	EV:	331.63	Union Investment	5.30 %	Equity Ratio:	42 %	
		Freefloat MC:	92.87			Net Fin. Debt / EBITDA:	7.0 x	
		Ø Trad. Vol. (30d):	70.25 th			Net Debt / EBITDA:	7.2 x	

Solid outlook based on a well-filled pipeline; PT down

Stated Figures FY/2024:					Comment on Figures:
in EUR m	2024	2024e	2023	yoy	• Figures matched our expectations at the upper end of the
Output (GWh)	441.1	458.8	407.8	8.2%	marking a solid year despite a challenging market environment.The yoy-decrease in sales and margin generation is a result of the solution of
Sales	36.1	36.9	44.8	-19.5%	the Finnish assets in 2023 and lower power-price levels in all key
op. EBITDA	23.0	23.3	30.3	-24.1%	 Clearvise made good progress with its portfolio by adding several to its pine line through its place.
margin	63.7%	63.1%	67.6%		to its pipeline through its clearPartners approach. The outlook for FY 2025 indicates strong top-line growth and is in
EBITDA	22.6	22.8	33.8	-33.0%	our expectations. We are positioned at the mid-point of the g
margin	62.7%	61.6%	75.3%		assuming average weather effects.

Clearvise published a decent set of figures that were in line with our expectations and at the upper end of the guidance range. Despite belowaverage weather effects and power-price headwinds, the company showed good operative performance thanks to its diversified and balanced portfolio structure. On a yearly basis, revenue and margin generation declined because of the sale of the Finnish assets in FY 2023. However, the portfolio optimisation was planned (sale of Finnish wind farms and the Samswegen biogas plant), and Clearvise has added several parks to its pipeline. Hence, we expect the P&L to return to growth and assume strong revenue and margin growth in the next years, backed by a solid balance sheet. In addition, management intends to propose a dividend of EUR 0.06 per share at this year's AGM.

The guidance for FY 2025 aligns with our expectations, indicating growing sales on the basis of an expanded operating portfolio. The French PV project Chassiecq (36.4 MW) and the German wind farm Weilrod 2 (18.6 MW) will contribute to this year's performance and management is guiding for sales of EUR 43.3-45.5m (WRe: EUR 44.13m) and operating EBITDA of EUR 27.1-29.2m (WRe: EUR 28.6m). Further assets are expected to be added to the portfolio in the coming years (France and Italy), and we see the clearPartners strategy as a key pillar in acquiring attractive assets and expanding the pipeline.

New price target takes into account the weak liquidity: Even though we consider the share to be highly undervalued at a price/book ratio below one, we have updated our valuation model to reflect the weak liquidity of the share and applied a higher beta. Our new price target is EUR 3.50, offering plenty of upside for investors.

Changes in E	stimates:						Comment on Changes:
FY End: 31.12. in EUR m	2025e (old)	+/-	2026e (old)	+/-	2027e (old)	+/-	 Minor changes to our financial model based on the published report.
Sales EBITDA	43.79 28.93	0.8 % -1.8 %	48.43 32.79	-1.2 % -0.4 %	43.10 31.37	14.0 % 7.2 %	

2.6 -	FY End: 31.12.	CAGR							
2.5 -	in EUR m	(24-27e)	2021	2022	2023	2024	2025e	2026e	2027e
2.4 -	Sales	10.8 %	32.88	65.16	44.84	36.08	44.13	47.87	49.15
2.3 -	Change Sales yoy		-9.8 %	98.2 %	-31.2 %	-19.5 %	22.3 %	8.5 %	2.7 %
22- M. M. V	Gross profit margin		98.9 %	99.6 %	98.9 %	100.0 %	100.0 %	100.0 %	100.0 %
22- 21 man of the of the second	EBITDA	14.1 %	21.84	48.17	33.78	22.62	28.40	32.65	33.62
2 - The Lagrand of W	Margin		66.4 %	73.9 %	75.3 %	62.7 %	64.4 %	68.2 %	68.4 %
1.9 - Warnen	EBIT	29.0 %	2.91	30.43	15.38	6.60	9.20	13.20	14.17
1.8 -	Margin		8.8 %	46.7 %	34.3 %	18.3 %	20.9 %	27.6 %	28.8 %
1.7 - Many how how have	Net income	119.8 %	-3.28	21.32	6.84	0.72	3.49	6.92	7.67
1.6 - 05/24 07/24 09/24 11/24 01/25 03/25	EPS	115.4 %	-0.06	0.34	0.09	0.01	0.05	0.09	0.10
Clearvise — CDAX (normalised)	EPS adj.	115.4 %	-0.06	0.34	0.09	0.01	0.05	0.09	0.10
	DPS	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Rel. Performance vs CDAX:	Dividend Yield		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	FCFPS		0.05	0.35	0.21	-0.26	-0.36	0.26	0.36
1 month: -2.3 %	FCF / Market cap		2.0 %	14.4 %	9.5 %	-13.1 %	-20.9 %	15.4 %	21.2 %
6 months: -14.4 %	EV / Sales		8.2 x	5.3 x	6.8 x	9.0 x	7.5 x	6.5 x	5.8 x
Year to date: -9.6 %	EV / EBITDA		12.4 x	7.1 x	9.0 x	14.4 x	11.7 x	9.6 x	8.5 x
Trailing 12 months: -36.2 %	EV / EBIT		93.1 x	11.3 x	19.8 x	49.2 x	36.1 x	23.7 x	20.1 x
	P/E		n.a.	7.1 x	25.0 x	196.0 x	34.0 x	18.9 x	17.0 x
Company events:	FCF Potential Yield		7.5 %	12.6 %	10.6 %	6.6 %	8.4 %	10.1 %	11.1 %
	Net Debt		139.35	190.18	135.43	177.23	204.07	184.35	157.23
	ROE		-6.9 %	20.1 %	4.3 %	0.5 %	2.2 %	4.2 %	4.4 %
	ROCE (NOPAT)		2.9 %	9.0 %	3.9 %	0.8 %	2.3 %	3.1 %	3.3 %
	Guidance:	op. EBITDA of	EUR 27.1-2	9.2m					

Analyst Jan Bauer jbauer@warburg-research.com +49 40 309537-155





Company Background

- Clearvise is a German IPP, focusing on the operation of European onshore wind and PV parks.
- The acquisition strategy of clearvise is based on three pillars (I) clearValue (II) clearSwitch and (III) clearPartners. The management has expanded the portfolio by more than 140% in only 3 years.
- All three route-to-markets are already proven with at least one successful acquisition. Primary object was the addition of PV projects to diversify the portfolio and optimize output.
- Within the clearScale growth strategy, clearvise targets to reach an portfolio size of 1GW (750MW operating & 250MW pipeline).
- To leverage the company's development know-how and use the opportunities of new technology's, the management can allocate up to 20% of the capital into development projects, cooperation or new technologies.

Competitive Quality

- A highly-experienced team of industry experts, capable of operating and optimizing the current portfolio, has developed a lean platform for the integration of further acquisitions.
- Clearvise has introduced a three-pronged market access strategy; clearVALUE, clearPARTNERS and clearSWITCH; to gain a competitive edge and establish a niche market position.
- The market access strategies target the current market as well as the market transition and should allow for profitable growth.
- The technical expertise of the management team and experience with the operation of the former ABO Invest portfolio allows for optimization measures, which will result in higher output.
- By expanding the investment focus of PV projects, the top-line and margins should stabilize further, providing highly visible and predictable cash-flows.



2



DCF n	nodel																				
			Detailed	d forecast pe	riod					Transitiona	l period										
Figures in EUI	Rm	i i	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	2038e	2039e	2040e	2041e	2042e	2043e
Sales			44.1	47.9	49.1	44.2	50.2	49.4	49.6	49.8	49.7	49.9	49.7	50.1	50.9	50.9	51.2	48.1	48.9	51.1	55.2
Sales change			22.3 %	8.5 %	2.7 %	-10.0 %	13.4 %	-1.6 %	0.5 %	0.5 %	-0.2 %	0.4 %	-0.5 %	0.9 %	1.5 %	0.1 %	0.6 %	-6.2 %	1.8 %	4.4 %	7.9 %
EBIT EBIT-margin			9.2 20.9 %	13.2 27.6 %	14.2 28.8 %	13.9 31.5 %	18.6 37.1 %	18.0 36.4 %	18.2 36.6 %	18.4 37.0 %	18.5 37.2 %	18.7 37.4 %	18.5 37.2 %	18.8 37.6 %	19.5 38.4 %	19.6 38.4 %	19.8 38.7 %	17.3 36.0 %	18.0 36.8 %	19.7 38.6 %	22.9 41.5 %
Tax rate (EBT	7		20.9 % 12.0 %	15.0 %	20.0 %	20.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %
NOPAT	,		8.1	11.2	11.3	11.1	14.0	13.5	13.6	13.8	13.9	14.0	13.9	14.1	14.6	14.7	14.9	13.0	13.5	14.8	17.2
Depreciation			19.2	19.4	19.4	21.1	21.1	21.1	21.1	21.0	20.8	20.8	20.8	20.8	20.7	20.7	20.7	20.7	20.7	20.7	20.7
in % of Sales			43.5 %	40.6 %	39.6 %	47.6 %	42.0 %	42.7 %	42.5 %	42.1 %	41.9 %	41.7 %	41.9 %	41.5 %	40.7 %	40.7 %	40.4 %	43.1 %	42.3 %	40.5 %	37.5 %
Change in pro			0.0	0.0	0.0	-6.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
- Working Cap			0.1	0.1	0.0	2.1	0.4	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.2	0.1	0.1	0.3
- Capex			49.4	6.5	0.0	28.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capex in % of	Sales		111.9 %	13.7 %	0.0 %	64.3 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Other			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Free Cash Flo	w (WACC-r	nodel)	-22.2	24.0	30.8	-5.0	34.6	34.6	34.7	34.8	34.7	34.8	34.7	34.9	35.3	35.4	35.6	33.9	34.1	35.4	37.6
PV of FCF			-21.8	22.5	27.4	-4.3	28.1	26.7	25.5	24.4	23.2	22.2	21.1	20.3	19.5	18.7	17.9	16.3	15.6	15.4	15.6
share of PVs				6.2 %						93.8	%										
																				T	erm. Value
2044e	2045e	2046e	2047e	2048e	2049e	2050e	2051e	2052e	2053e	2054e	2055e	2056e	2057e	2058e	2059e	2060e	2061e	2062e	2063e	2064e	
47.5	48.4	39.6	39.9	40.1	40.4		45.4	46.0	43.6	44.2	44.8	43.7	33.4	33.8	21.3	16.0	16.1	10.6	10.7	10.8	
-13.8 %	1.7 %	-18.2 %	0.8 %	0.5 %	0.8 %	10.7 %	1.3 %	1.3 %	-5.2 %	1.3 %	1.3 %	-2.4 %	-23.5 %	1.3 %	-37.1 %	-24.9 %	1.1 %	-34.4 %	1.0 %	1.0 %	0.0 %
22.9 48.1 %	37.0 76.5 %	30.0 75.9 %	31.3 78.4 %	31.7 79.1 %	32.0 79.1 %	35.4 79.1 %	35.9 79.1 %	36.3 79.1 %	34.5 79.1 %	34.9 79.1 %	35.4 79.1 %	34.5 79.1 %	26.4 79.0 %	26.7 79.0 %	16.8 79.0 %	12.6 79.0 %	12.7 79.0 %	8.4 78.9 %	8.4 78.9 %	8.5 79.0 %	
25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	
17.2	27.7	22.5	23.5	23.8	24.0	26.5	26.9	27.3	25.8	26.2	26.5	25.9	19.8	20.1	12.6	9.5	9.6	6.3	6.3	6.4	
14.7	1.3	1.3	0.3	0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
31.0 %	2.6 %	3.2 %	0.7 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.1 %	0.1 %	0.1 %	0.1 %	0.1 %	0.1 %	
0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
-0.5	0.1	-0.6	0.0	0.0	0.0	0.3	0.0	0.0	-0.2	0.0	0.0	-0.1	-0.7	0.0	-0.8	-0.3	0.0	-0.4	0.0	-0.7	
0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	0.0 0.0 %	
0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	2.0	3.0	4.0	
32.4	28.9	24.4	23.7	23.8	24.0		26.9	27.2	26.0	26.2	26.5	26.0	20.5	20.0	13.4	9.8	8.6	4.6	3.3	4.0	
02.4	20.3	24.4	23.1	20.0	24.0	20.3	20.9	21.2	20.0	20.2	20.0	20.0	20.0	20.0	13.4	3.0	0.0	4.0	0.0	0.1	
10.0	10.9	8.8	8.1	7.8	7.5	7.8	7.6	7.4	6.7	6.4	6.2	5.8	4.4	4.1	2.6	1.8	1.5	0.8	0.5	0.5	0.0
12.8	10.5	0.0	0.1		1.0	1.0	1.0		0.7	0.4	0.2	5.6	4.4	4.1	2.0	1.0	1.5	0.0	0.5	0.5	0.0

Model parameter									
Derivation of WACC:		Derivation of Beta:							
Debt ratio	45.0 %	Financial Strength	0.70						
Cost of debt	3.0 %	Liquidity	1.00						
Market return	8.3 %	Cyclicality	0.60						
Risk free rate	2.8 %	Transparency	0.80						
Risk premium	5.5 %	Others	0.80						
Cost of equity	7.0 %								
WACC	4.88 %	Beta	0.78						

Sensitivity Value	per share (EUR)
-------------------	-----------------

	Terminal Growth							Delta EBIT-margin							
Beta	(WACC)	-0.75 %	-0.50 %	-0.25 %	0.00 %	0.25 %	0.50 %	0.75 %	-1.50 pp	-1.00 pp	-0.50 pp	0.0	0.50 pp	1.00 pp	1.50 pp
1.11	(5.9 %)	2.78	2.78	2.78	2.78	2.78	2.78	2.78	2.67	2.71	2.75	2.78	2.82	2.86	2.90
0.95	(5.4 %)	3.14	3.14	3.14	3.14	3.14	3.14	3.14	3.02	3.06	3.10	3.14	3.18	3.22	3.26
0.86	(5.1 %)	3.33	3.33	3.33	3.33	3.33	3.33	3.33	3.21	3.25	3.29	3.33	3.37	3.41	3.45
0.78	(4.9 %)	3.53	3.53	3.53	3.53	3.53	3.53	3.53	3.41	3.45	3.49	3.53	3.57	3.61	3.66
0.70	(4.6 %)	3.74	3.74	3.74	3.74	3.74	3.74	3.74	3.61	3.65	3.70	3.74	3.78	3.83	3.87
0.61	(4.4 %)	3.96	3.96	3.96	3.96	3.96	3.96	3.96	3.83	3.87	3.92	3.96	4.00	4.05	4.09
0.45	(3.9 %)	4.44	4.44	4.44	4.44	4.44	4.44	4.44	4.29	4.34	4.39	4.44	4.48	4.53	4.58

Valuation (m)

Pension liabilities Hybrid capital Minority interest Market val. of investments

Liquidity Equity Value

Present values until 2064e Terminal Value Financial liabilities 454.5 0.0 195.1 6.7 0.0

11.2 0.0 24.6

266.0

No. of shares (m) Value per share

(EUR)

75.4

3.53

Our Warburg IPP-DCF approach is a modified valuation approach for the valuation of renewable energy assets.

Since we can calculate top-line and margin generation of each park over the useful live, we extend our DCF-approach.

We do not apply a terminal value to our valuation, reflecting the limited life of renewable energy assets.

For our calculation, we assume a useful life of 30 years for onshore wind and 35 years for PV.

We only include the current portfolio size of clearvise in our Warburg IPP-DCF.



Valuation							
	2021	2022	2023	2024	2025e	2026e	2027e
Price / Book	2.3 x	1.0 x	1.1 x	0.9 x	0.8 x	0.8 x	0.7 x
Book value per share ex intangibles	0.88	2.08	2.11	2.12	2.16	2.26	2.36
EV / Sales	8.2 x	5.3 x	6.8 x	9.0 x	7.5 x	6.5 x	5.8 x
EV / EBITDA	12.4 x	7.1 x	9.0 x	14.4 x	11.7 x	9.6 x	8.5 x
EV / EBIT	93.1 x	11.3 x	19.8 x	49.2 x	36.1 x	23.7 x	20.1 x
EV / EBIT adj.*	93.1 x	11.3 x	19.8 x	49.2 x	36.1 x	23.7 x	20.1 x
P / FCF	49.4 x	7.0 x	10.5 x	n.a.	n.a.	6.5 x	4.7 x
P/E	n.a.	7.1 x	25.0 x	196.0 x	34.0 x	18.9 x	17.0 x
P / E adj.*	n.a.	7.1 x	25.0 x	196.0 x	34.0 x	18.9 x	17.0 x
Dividend Yield	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield (on market EV)	7.5 %	12.6 %	10.6 %	6.6 %	8.4 %	10.1 %	11.1 %
*Adjustments made for: -							

Company Specific Items							
	2021	2022	2023	2024	2025e	2026e	2027e
Output in GWh	367	495	534	441	609	614	614

Consolidated profit & loss



In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Sales	32.88	65.16	44.84	36.08	44.13	47.87	49.15
Change Sales yoy	-9.8 %	98.2 %	-31.2 %	-19.5 %	22.3 %	8.5 %	2.7 %
Increase / decrease in inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Own work capitalised	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Sales	32.88	65.16	44.84	36.08	44.13	47.87	49.15
Material expenses	0.35	0.28	0.47	0.00	0.00	0.00	0.00
Gross profit	32.53	64.88	44.37	36.08	44.13	47.87	49.15
Gross profit margin	98.9 %	99.6 %	98.9 %	100.0 %	100.0 %	100.0 %	100.0 %
Personnel expenses	0.66	1.52	1.59	2.28	2.30	2.40	2.46
Other operating income	0.22	0.51	6.67	2.46	1.00	1.00	1.00
Other operating expenses	10.25	15.69	15.67	13.64	14.43	13.82	14.06
Unfrequent items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	21.84	48.17	33.78	22.62	28.40	32.65	33.62
Margin	66.4 %	73.9 %	75.3 %	62.7 %	64.4 %	68.2 %	68.4 %
Depreciation of fixed assets	18.93	17.74	18.41	16.02	19.19	19.45	19.45
EBITA	2.91	30.43	15.38	6.60	9.20	13.20	14.17
Amortisation of intangible assets	0.00	1.25	1.27	0.00	0.00	0.00	0.00
Goodwill amortisation	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT	2.91	30.43	15.38	6.60	9.20	13.20	14.17
Margin	8.8 %	46.7 %	34.3 %	18.3 %	20.9 %	27.6 %	28.8 %
EBIT adj.	2.91	30.43	15.38	6.60	9.20	13.20	14.17
Interest income	0.02	3.39	0.40	0.72	0.40	0.40	0.40
Interest expenses	4.72	7.48	7.40	5.46	5.64	5.46	4.98
Other financial income (loss)	0.02	0.00	0.00	0.00	0.00	0.00	0.00
EBT	-1.81	26.34	8.37	1.86	3.97	8.14	9.59
Margin	-5.5 %	40.4 %	18.7 %	5.1 %	9.0 %	17.0 %	19.5 %
Total taxes	1.47	5.02	1.53	1.13	0.48	1.22	1.92
Net income from continuing operations	-3.28	21.32	6.84	0.72	3.49	6.92	7.67
Income from discontinued operations (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net income before minorities	-3.28	21.32	6.84	0.72	3.49	6.92	7.67
Minority interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net income	-3.28	21.32	6.84	0.72	3.49	6.92	7.67
Margin	-10.0 %	32.7 %	15.2 %	2.0 %	7.9 %	14.5 %	15.6 %
Number of shares, average	53.78	63.45	75.36	75.36	75.36	75.36	75.36
EPS	-0.06	0.34	0.09	0.01	0.05	0.09	0.10
EPS adj.	-0.06	0.34	0.09	0.01	0.05	0.09	0.10
*Adjustments made for:							

Guidance: op. EBITDA of EUR 27.1-29.2m

Financial Ratios

	2021	2022	2023	2024	2025e	2026e	2027e
	2021	LULL	2025	2024	20230	20200	20270
Total Operating Costs / Sales	33.6 %	26.1 %	24.7 %	37.3 %	35.6 %	31.8 %	31.6 %
Operating Leverage	7.0 x	9.7 x	1.6 x	2.9 x	1.8 x	5.1 x	2.8 x
EBITDA / Interest expenses	4.6 x	6.4 x	4.6 x	4.1 x	5.0 x	6.0 x	6.7 x
Tax rate (EBT)	-80.9 %	19.1 %	18.3 %	61.0 %	12.0 %	15.0 %	20.0 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Sales, EBITDA in EUR m

Source: Warburg Research



Operating Performance in %



Performance per Share



Source: Warburg Research

Consolidated balance sheet



In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Assets							
Goodwill and other intangible assets	5.57	0.00	0.00	0.11	0.11	0.11	0.11
thereof other intangible assets	0.00	0.00	0.00	0.11	0.11	0.11	0.11
thereof Goodwill	5.57	0.00	0.00	0.00	0.00	0.00	0.00
Property, plant and equipment	191.33	352.58	291.46	327.75	357.95	345.05	325.60
Financial assets	0.19	0.88	0.90	0.52	0.52	0.52	0.52
Other long-term assets	0.00	0.05	2.64	0.07	0.02	0.02	0.07
Fixed assets	197.09	353.51	295.01	328.45	358.65	345.75	326.30
Inventories	0.29	0.23	0.00	0.10	0.10	0.20	0.20
Accounts receivable	5.85	6.20	5.18	4.14	5.10	5.50	5.60
Liquid assets	23.20	77.67	47.99	24.58	4.61	6.27	18.89
Other short-term assets	4.49	13.74	14.91	19.00	19.00	19.00	19.00
Current assets	33.83	97.84	68.08	47.82	28.80	30.97	43.69
Total Assets	230.90	451.30	363.10	376.30	387.50	376.70	370.00
Liabilities and shareholders' equity							
Subscribed capital	57.40	75.36	75.36	75.36	75.36	75.36	75.36
Capital reserve	25.59	44.75	44.75	44.75	44.75	44.75	44.75
Retained earnings	0.99	0.00	0.00	-0.61	2.88	9.80	17.48
Other equity components	-27.78	35.84	39.00	40.22	40.22	40.22	40.22
Shareholders' equity	56.20	155.95	159.11	159.72	163.21	170.13	177.80
Minority interest	4.88	0.00	0.01	0.10	0.10	0.10	0.10
Total equity	61.08	155.95	159.11	159.82	163.31	170.23	177.90
Provisions	3.02	12.54	11.92	8.34	8.34	8.34	8.34
thereof provisions for pensions and similar obligations	0.00	7.08	6.31	6.69	6.69	6.69	6.69
Financial liabilities (total)	162.55	260.76	177.11	195.12	201.99	183.93	169.43
Short-term financial liabilities	0.00	51.52	28.20	18.23	8.23	0.00	0.00
Accounts payable	1.42	5.81	2.61	3.67	4.50	4.90	5.00
Other liabilities	2.88	16.29	12.33	9.32	9.32	9.32	9.32
Liabilities	169.86	295.40	203.97	216.45	224.14	206.49	192.08
Total liabilities and shareholders' equity	230.90	451.30	363.10	376.30	387.50	376.70	370.00

Financial Ratios

	2021	2022	2023	2024	2025e	2026e	2027e
Efficiency of Capital Employment							
Operating Assets Turnover	0.2 x	0.2 x	0.2 x	0.1 x	0.1 x	0.1 x	0.2 x
Capital Employed Turnover	0.2 x	0.2 x	0.2 x	0.1 x	0.1 x	0.1 x	0.1 x
ROA	-1.7 %	6.0 %	2.3 %	0.2 %	1.0 %	2.0 %	2.4 %
Return on Capital							
ROCE (NOPAT)	2.9 %	9.0 %	3.9 %	0.8 %	2.3 %	3.1 %	3.3 %
ROE	-6.9 %	20.1 %	4.3 %	0.5 %	2.2 %	4.2 %	4.4 %
Adj. ROE	-6.9 %	20.1 %	4.3 %	0.5 %	2.2 %	4.2 %	4.4 %
Balance sheet quality							
Net Debt	139.35	190.18	135.43	177.23	204.07	184.35	157.23
Net Financial Debt	139.35	183.10	129.12	170.54	197.38	177.66	150.54
Net Gearing	228.2 %	121.9 %	85.1 %	110.9 %	125.0 %	108.3 %	88.4 %
Net Fin. Debt / EBITDA	638.2 %	380.1 %	382.2 %	754.0 %	695.1 %	544.1 %	447.7 %
Book Value / Share	1.0	2.1	2.1	2.1	2.2	2.3	2.4
Book value per share ex intangibles	0.9	2.1	2.1	2.1	2.2	2.3	2.4



COMMENT

Published 28.04.2025

6

Consolidated cash flow statement



In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Net income	-3.28	21.32	6.84	0.72	3.49	6.92	7.67
Depreciation of fixed assets	18.93	16.49	17.13	16.02	19.19	19.45	19.45
Amortisation of goodwill	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Amortisation of intangible assets	0.00	1.25	1.27	0.00	0.00	0.00	0.00
Increase/decrease in long-term provisions	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other non-cash income and expenses	5.25	10.62	-8.68	-1.94	0.00	0.00	0.00
Cash Flow before NWC change	20.90	49.68	16.56	14.81	22.69	26.37	27.12
Increase / decrease in inventory	-1.19	0.00	0.00	0.00	0.00	-0.10	0.00
Increase / decrease in accounts receivable	-1.23	0.00	0.00	0.00	-0.96	-0.40	-0.10
Increase / decrease in accounts payable	0.00	0.00	0.00	0.00	0.83	0.40	0.10
Increase / decrease in other working capital positions	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / decrease in working capital (total)	-2.42	0.00	0.00	0.00	-0.13	-0.10	0.00
Net cash provided by operating activities [1]	18.48	49.68	16.56	14.81	22.56	26.27	27.12
Investments in intangible assets	0.00	0.00	0.00	-0.11	0.00	0.00	0.00
Investments in property, plant and equipment	-15.82	-27.79	-0.45	-34.05	-49.39	-6.55	0.00
Payments for acquisitions	-14.54	-27.21	-9.81	0.69	0.00	0.00	0.00
Financial investments	0.00	0.00	0.06	0.00	0.00	0.00	0.00
Income from asset disposals	0.00	0.00	0.01	2.90	0.00	0.00	0.00
Net cash provided by investing activities [2]	-30.35	-55.00	9.21	-28.61	-49.39	-6.55	0.00
Change in financial liabilities	1.69	26.50	-48.59	-5.40	6.87	-18.05	-14.50
Dividends paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of own shares	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital measures	20.72	37.12	0.00	0.00	0.00	0.00	0.00
Other	-4.68	-3.89	-6.87	-4.21	0.00	0.00	0.00
Net cash provided by financing activities [3]	17.73	59.73	-55.45	-9.61	6.87	-18.05	-14.50
Change in liquid funds [1]+[2]+[3]	5.86	54.42	-29.68	-23.41	-19.97	1.67	12.62
Effects of exchange-rate changes on cash	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash and cash equivalent at end of period	23.18	77.62	47.99	24.58	4.61	6.27	18.89

Financial Ratios

	2021	2022	2023	2024	2025e	2026e	2027e
Cash Flow							
FCF	2.66	21.89	16.12	-19.35	-26.84	19.72	27.12
Free Cash Flow / Sales	8.1 %	33.6 %	35.9 %	-53.6 %	-60.8 %	41.2 %	55.2 %
Free Cash Flow Potential	20.37	43.15	32.25	21.49	27.92	31.43	31.70
Free Cash Flow / Net Profit	-81.0 %	102.7 %	235.7 %	-2677.5 %	-768.7 %	285.0 %	353.5 %
Interest Received / Avg. Cash	0.1 %	6.7 %	0.6 %	2.0 %	2.7 %	7.4 %	3.2 %
Interest Paid / Avg. Debt	3.1 %	3.5 %	3.4 %	2.9 %	2.8 %	2.8 %	2.8 %
Management of Funds							
Investment ratio	48.1 %	42.7 %	1.0 %	94.7 %	111.9 %	13.7 %	0.0 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	83.6 %	156.6 %	2.4 %	213.2 %	257.3 %	33.7 %	0.0 %
Avg. Working Capital / Sales	14.2 %	4.1 %	3.6 %	4.4 %	1.4 %	1.6 %	1.6 %
Trade Debtors / Trade Creditors	413.1 %	106.7 %	198.6 %	112.8 %	113.3 %	112.2 %	112.0 %
Inventory Turnover	1.2 x	1.2 x	n.a.	0.0 x	0.0 x	0.0 x	0.0 x
Receivables collection period (days)	65	35	42	42	42	42	42
Payables payment period (days)	1,460	7,496	2,020	n.a.	n.a.	n.a.	n.a.
Cash conversion cycle (Days)	-1,094	-7,162	n.a.	n.a.	n.a.	n.a.	n.a.

CAPEX and Cash Flow in EUR m



Free Cash Flow Generation

COMMENT

Published 28.04.2025

7

Working Capital



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a share of more than 5% of the equity capital of the analysed company.
- -2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- -4 MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has	been made	accessible	to the	company	/ anal\	/sed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Clearvise	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A1EWXA4.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	145	73
Hold	43	22
Sell	6	3
Rating suspended	5	3
Total	199	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	37	74
Hold	9	18
Sell	1	2
Rating suspended	3	6
Total	50	100

PRICE AND RATING HISTORY CLEARVISE AS OF 28.04.2025



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode Head of Equities	+49 40 3282-2678 mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research Henner Rüschmeier	+49 40 309537-280 mheider@warburg-research.com +49 40 309537-270	Hannes Müller Software, IT Andreas Pläsier	+49 40 309537-255 hmueller@warburg-research.com +49 40 309537-246
Head of Research	hrueschmeier@warburg-research.com	Banks, Financial Services	aplaesier@warburg-research.com
Stefan Augustin Cap. Goods, Engineering	+49 40 309537-168 saugustin@warburg-research.com	Malte Schaumann Technology	+49 40 309537-170 mschaumann@warburg-research.com
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com
Christian Cohrs Industrials & Transportation	+49 40 309537-175 ccohrs@warburg-research.com	Simon Stippig Real Estate, Telco	+49 40 309537-265 sstippig@warburg-research.com
Dr. Christian Ehmann BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Felix Ellmann	+49 40 309537-120	Robert-Jan van der Horst	+49 40 309537-290
Software, IT Jörg Philipp Frey Retail, Consumer Goods	fellmann@warburg-research.com +49 40 309537-258 jfrey@warburg-research.com	Technology Andreas Wolf Software, IT	rvanderhorst@warburg-research.com +49 40 309537-140 awolf@warburg-research.com
Marius Fuhrberg	+49 40 309537-185		
Financial Services Fabio Hölscher	mfuhrberg@warburg-research.com +49 40 309537-240		
Automobiles, Car Suppliers	fhoelscher@warburg-research.com		
Philipp Kaiser Real Estate, Construction	+49 40 309537-260 pkaiser@warburg-research.com		
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com		
INSTITUTIONAL EQUI	TY SALES		
Klaus Schilling	+49 69 5050-7400	Sascha Propp	+49 40 3282-2656
Head of Equity Sales, Germany Tim Beckmann	kschilling@mmwarburg.com +49 40 3282-2665	France	spropp@mmwarburg.com
United Kingdom	tbeckmann@mmwarburg.com		
Jens Buchmüller	+49 69 5050-7415		
Scandinavia, Austria Matthias Fritsch	jbuchmueller@mmwarburg.com +49 40 3282-2696	Leyan Ilkbahar	+49 40 3282-2695
United Kingdom, Ireland	mfritsch@mmwarburg.com	Roadshow/Marketing	lilkbahar@mmwarburg.com
Rudolf Alexander Michaelis	+49 40 3282-2649	Antonia Möller	+49 69 5050-7417
Germany	rmichaelis@mmwarburg.com	Roadshow/Marketing	amoeller@mmwarburg.com
Roman Alexander Niklas Switzerland, Poland, Italy	+49 69 5050-7412 rniklas@mmwarburg.com	Juliane Niemann Roadshow/Marketing	+49 40 3282-2694 jniemann@mmwarburg.com
SALES TRADING			, .
Oliver Merckel	+49 40 3282-2634	Sebastian Schulz	+49 40 3282-2631
Head of Sales Trading	omerckel@mmwarburg.com	Designated Sponsoring	sschulz@mmwarburg.com
Bastian Quast	+49 40 3282-2701	Jörg Treptow Designated Sponsoring	+49 40 3282-2658 itreptow@mmwarburg.com
Sales Trading Christian Salomon	bquast@mmwarburg.com +49 40 3282-2685	Designated Sponsoning	Jirepiow@mmwarburg.com
Sales Trading	csalomon@mmwarburg.com		
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be fo	ound under:		
Warburg Research	research.mmwarburg.com/en/index.html	LSEG	www.lseg.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please contact	ct:		
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com